SCHEMBL2120802

SCHEMBL2120802

N#Cc1ccc(OC2CCC(OCC(=O)N3CCN(c4ccc(C(F)(F)F)cn4)CC3)CC2)cc1C(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.51
IDE P14735 1/20 0.51
HPGD P15428 1/20 0.47
PRKAA2 P54646 2/20 0.45
RET P07949 1/20 0.43
LMNA P02545 4/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 2/20 0.42
HRH3 Q9Y5N1 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
TIPARP Q7Z3E1 3/20 0.42
AR P10275 1/20 0.41
DPP4 P27487 1/20 0.41
ABL1 P00519 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2617832 1.00 SMN1; SMN2 (0.51) SMN1; SMN2IDEHPGDPRKAA2RET
SCHEMBL2617777 1.00 SMN1; SMN2 (0.51) SMN1; SMN2IDEHPGDPRKAA2RET
SCHEMBL2120603 0.92 AR (0.50) SMN1; SMN2IDEPRKAA2TIPARPAR
SCHEMBL2617834 0.92 AR (0.50) SMN1; SMN2IDEPRKAA2TIPARPAR
SCHEMBL2617778 0.91 PRKAA2 (0.42) SMN1; SMN2IDEPRKAA2RETLMNA
SCHEMBL2617835 0.91 PRKAA2 (0.42) SMN1; SMN2IDEPRKAA2RETLMNA
SCHEMBL2120388 0.91 PRKAA2 (0.42) SMN1; SMN2IDEPRKAA2RETLMNA
SCHEMBL2617865 0.91 SMN1; SMN2 (0.43) SMN1; SMN2IDEHPGDPRKAA2RET
SCHEMBL2119282 0.91 SMN1; SMN2 (0.43) SMN1; SMN2IDEHPGDPRKAA2RET
SCHEMBL2617802 0.91 SMN1; SMN2 (0.43) SMN1; SMN2IDEHPGDPRKAA2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507474-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2013-08-13 US disclosed
EP-2443091-B1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INT BV (NL) 2013-04-03 EP disclosed
EP-2443091-A1 ANTHELMINTIC AGENTS AND THEIR USE Intervet International B.V. (NL) 2012-04-25 EP disclosed
US-20120094981-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2012-04-19 US disclosed
WO-2010146083-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094981-A1 ANTHELMINTIC AGENTS AND THEIR USE ABCB11, ACHE, CMA1 SMN1; SMN2 4488/4885IDE 1072/4885HPGD 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.